Ravenquest Biomed Inc. (CNSX:RQB) entered into a letter of intent to acquire 51% stake in 1090252 B.C. Ltd. on June 14, 2018. The 51% stake can be redeemed by 1090252 B.C. Ltd. at any time after it receives a license to produce under the ACMPR, and in consideration RavenQuest will be granted an ongoing royalty of 15% of the gross revenue from production at the facility developed by 1090252 B.C. Ltd. Trevor Hinds, President and Chief Executive Officer of 1090252 B.C. Ltd., and his team will join Ravenquest Biomed. Completion of the transaction is subject to completion of due diligence, the negotiation of definitive documentation, and the receipt of any required regulatory approvals. Ravenquest Biomed Inc. (CNSX:RQB) cancelled the acquisition of 51% stake in 1090252 B.C. Ltd. on June 14, 2019.